Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-575	-569	-607	-707.42	-454.03
Depreciation & Amortization	35	36	26	18.22	13.24
Stock-Based Compensation	153	158	135	130.38	104.95
Other Adjustments	-56	-53	-13	116.49	60.38
Change in Receivables	-31	-34	-23	-12.07	-5.43
Changes in Inventories	-6	-11	-7	-9.7	-3.12
Changes in Accounts Payable	24	47	-1	79.85	32.31
Changes in Other Operating Activities	-10	12	15	3.8	-87
Operating Cash Flow	-466	-414	-475	-380.47	-338.7
Capital Expenditures	-6	-7	-44	-116.12	-73.09
Purchases of Intangible Assets	-15	-13	-3	-30	-
Purchases of Investments	-186	-409	-526	-614.74	-1,012
Proceeds from Sale of Investments	444	413	747	545.08	890.85
Payments for Business Acquisitions	-	-	-	-75.03	-
Other Investing Activities	-1	-2	-6	-0.84	-0.94
Investing Cash Flow	236	-18	168	-291.65	-195.37
Issuance of Common Stock	86	392	387	10.81	119.04
Net Common Stock Issued (Repurchased)	86	392	387	10.81	119.04
Other Financing Activities	392	7	1	490.4	-0.49
Financing Cash Flow	478	399	388	501.21	118.55
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	4	-2	-1.08	-1.19
Net Cash Flow	252	-35	81	-171.98	-416.71
Free Cash Flow	-472	-421	-519	-496.59	-411.79
FCF Margin	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%
Free Cash Flow Per Share	-4.79	-4.65	-7.06	-7.10	-6.07
Levered Free Cash Flow	-538	-492	-618	-731.38	-571.68
Unlevered Free Cash Flow	-501.75	-460.89	-578.13	-678.15	-500.27

Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q